Nutrition, Metabolism & Cardiovascular Diseases
Volume 21, Issue 5 , Pages 315-322 , May 2011

The role of HDL cholesterol in metabolic syndrome predicting cardiovascular events. The Gubbio population study

  • A. Menotti

      Affiliations

    • Association for Cardiac Research – Associazione per la Ricerca Cardiologica, Via Arco di Parma 13, Rome 00186, Italy
    • ,
  • M. Lanti

      Affiliations

    • Association for Cardiac Research – Associazione per la Ricerca Cardiologica, Via Arco di Parma 13, Rome 00186, Italy
    • Corresponding Author InformationCorresponding author. Tel./fax: +39 06 77591715.
    • ,
  • A. Zanchetti

      Affiliations

    • Centre of Clinical Physiology and Hypertension, University of Milan, and Istituto Auxologico Italiano, Milan, Italy
    • ,
  • G. Botta

      Affiliations

    • Merck Sharp & Dohme Italy, Rome, Italy
    • ,
  • M. Laurenzi

      Affiliations

    • Global Alliance for TB Drug Development, New York, NY, USA
    • ,
  • O. Terradura-Vagnarelli

      Affiliations

    • Centre of Preventive Medicine, Gubbio, Italy
    • ,
  • M. Mancini

      Affiliations

    • Department of Clinical and Experimental Medicine, University Federico II, Naples, Italy

Received 19 March 2009 ,Revised 2 September 2009 ,Accepted 10 November 2009.

References 

  1. www.pubmed.org, Key words: Metabolic Syndrome. [accessed June 2009].
  2. Trevisan M, Liu J, Bahsas FB. Menotti A for the risk factor and life expectancy research group. Syndrome X and mortality: a population based study. Am J Epidemiol. 1998;148:958–966
  3. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288:2709–2715
  4. Bonora E, Kiechl S, Willeit J, Oberhollenzer E, Egger G, Bonadonna RC, et al. Carotid atherosclerosis and coronary heart disease in the metabolic syndrome: prospective data from the Brunek study. Diabetes Care. 2003;26:1251–1257
  5. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome and risk of incident cardiovascular events: an 8-year follow-up of 14719 initially health American women. Circulation. 2003;107:391–397
  6. Ford ES. The metabolic syndrome and mortality from cardiovascular disease and all-cause findings from the National Health and Nutrition Examination Survey II Mortality Study. Atherosclerosis. 2004;173:309–314
  7. Hunt KJ, Resendez R, Williams K, Haffner SM, Stern MP. National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation. 2004;110:1251–1257
  8. Malik S, Wong ND, Franklin SS, Kamath TV, L'Italien GJ, Pio JR, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular and all causes in United States adults. Circulation. 2004;110:1245–1250
  9. McNeill AM, Rosamond WD, Girman CJ, Golden SH, Schmidt MI, East HE, et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in atherosclerosis risk in communities. Diabetes Care. 2005;28:385–390
  10. Maggi S, Noale M, Gallina P, Bianchi D, Marzari C, Limongi F, et al. ILSA Working Group. Metabolic syndrome, diabetes, and cardiovascular disease in an elderly Caucasian colour: the Italian Longitudinal Study on Aging. J Gerontol A Biol Sci Med Sci. 2006;61:505–510
  11. Gami AS, Witt BJ, Howard DE, Erwin PJ, Gami LA, Somers VK, et al. Metabolic syndrome and risk of cardiovascular events and death. A systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol. 2007;49:403–414
  12. Kahn R, Buse J, Ferranini E, Stern M. The metabolic syndrome. Time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2005;28:2289–2304
  13. Mancia G, Bombelli M, Corrao G, Facchetti R, Madotto F, Giannattasio C, et al. Metabolic syndrome in the Pressioni Arteriose Monitorate E Loro Associazioni (PAMELA) study: daily life blood pressure, cardiac damage, and prognosis. Hypertension. 2007;9:10–12
  14. National Cholesterol Education Program (NCEP) Expert Panel on Detection . Evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation. 2002;106:3143–3421
  15. Alberti KG, Zimmer P, Shaw J. The IDF Epidemiological Task Force Consensus Group. The metabolic syndrome: a new worldwide definition. Lancet. 2005;336:1059–1062
  16. Balkau B, Charles MA. Comments of the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med. 1999;16:442–443
  17. Alberti KG, Zimmer PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1. Diagnosis and classification of diabetes mellitus: provisional report of a WHO consultation. Diabet Med. 1998;15:539–553
  18. Abbott RD, Wilson PW, Kannel WB, Castelli WP. High density lipoprotein cholesterol, total cholesterol screening, and myocardial infarction. The Framingham Study. Arteriosclerosis (Dallas, Tex). 1988;8:207–211
  19. Assmann G, Schulte H, von Eckardstein A, Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis. 1996;124(Suppl.):S11–S20
  20. Goldbourt U. HDL cholesterol and 24-year mortality. Int J Epidemiol. 1986;15:143–144
  21. Jousilahti P, Vartiainen E, Tuomilehto J, Puska P. Sex, age, cardiovascular risk factors, and coronary heart disease: a prospective follow-up study of 14 786 middle-aged men and women in Finland. Circulation. 1999;99(9):1165–1172
  22. Kitamura A, Iso H, Naito Y, Iida M, Konishi M, Folsom AR, et al. High-density lipoprotein cholesterol and premature coronary heart disease in urban Japanese men. Circulation. 1994;89(6):2533–2539
  23. Luc G, Bard JM, Ferrieres J, Evans A, Amouyel P, Arveiler D, et al. Value of HDL cholesterol, apolipoprotein A-I, lipoprotein A-I, and lipoprotein A-I/A-II in prediction of coronary heart disease: the PRIME Study. Prospective Epidemiological Study of Myocardial Infarction. Arterioscler Thromb Vasc Biol. 2002;22(7):1155–1161
  24. Miller GJ, Miller NE. Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease. Lancet. 1975;1(7897):16–19
  25. Sharrett AR, Ballantyne CM, Coady SA, Heiss G, Sorlie PD, Catellier D, et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2001;104(10):1108–1113
  26. Stensvold I, Urdal P, Thurmer H, Tverdal A, Lund-Larsen PG, Foss OP. High-density lipoprotein cholesterol and coronary, cardiovascular and all cause mortality among middle-aged Norwegian men and women. Eur Heart J. 1992;13(9):1155–1163
  27. Menotti A, Spagnolo A, Scanga M, Dima F. Multivariate prediction of coronary deaths in a 10 year follow-up of an Italian occupational male cohort. Acta Cardiol. 1992;47:311–320
  28. Menotti A, Lanti M, Puddu PE, Mancini M, Zanchetti A, Cirillo M, et al. First risk functions for prediction of coronary and cardiovascular disease incidence in the Gubbio Population Study. Ital Heart J. 2000;1:394–399
  29. Menotti A, Lanti M, Agabiti-Rosei E, Carratelli L, Cavera G, Dormi A, et al. New tools for prediction of cardiovascular disease risk derived from Italian population studies. Nutr Metab Cardiovasc Dis. 2005;15:426–440
  30. Palmieri L, Donfrancesco C, Giampaoli S, Trojani M, Panico S, Vanuzzo D, et al. Favorable cardiovascular risk profile and 10-year coronary heart disease incidence in women and men: results from the Progetto Cuore. Eur J Cardiovasc Prev Rehabil. 2006;13:562–570
  31. Prospective Studies Collaboration. Blood cholesterol and vascular mortality by age, sex and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55000 vascular deaths. Lancet. 2007;370:1829–1839
  32. Cooney MT, Dudina A, De Bacquer D, Wilhelmsen L, Sans S, Menotti A, et al. HDL cholesterol protects against cardiovascular disease in both genders, at all ages and at all levels of risk. Atherosclerosis. 2009, March 19th;(Epub ahead of print)
  33. Barter Ph, Rye KA. High density cholesterol: the new target. A handbook for clinicians. Birmingham, UK: Sherborne Gibbs Limited; 2005;
  34. Carlson LA. Niaspan, the prolonged release preparation of nicotinic acid (niacin), the broad-spectrum lipid drug. Int J Clin Pract. 2004;58:706–713
  35. Laurenzi M, Trevisan M. Sodium–lithium countertransport and blood pressure: the Gubbio Population Study. Hypertension. 1989;13:408–415
  36. Laurenzi M, Cirillo M, Panarelli W, Trevisan M, Stamler R, Dyer AR, et al. Baseline sodium–lithium countertransport and 6-year incidence of hypertension: the Gubbio Study. Circulation. 1997;95:581–587
  37. Menotti A, Lanti M, Angeletti M, Botta GF, Cirillo M, Laurenzi M, et al. Twenty-year cardiovascular and all-cause mortality trends, and changes in cardiovascular risk factors in Gubbio, Italy. The role of blood pressure changes. J Hypertens. 2009;27:266–274
  38. Rose G, Blackburn H. Cardiovascular survey methods. Geneva: World Health Organization; 1968;
  39. Morisi G, Macchia T, Angelico P, Pacioni F, Zucca A. Determinazione automatica di trigliceridi, colesterolo, glucosio ed acido urico: prospettive d'impiego in screening di medicina preventiva (Automatic measurement of triglycerides, cholesterol, glucose and uric acid: perspective use in screening of preventive medicine), Ann Ist Super Sanita. 1979;15:239–261
  40. Buongiorno AM, Macchia T, Morisi G, Zucca A. HDL colesterolo:confronto tra metodi e prospettive di impiego nella prevenzione dell'arteriosclerosi (HDL cholesterol: comparison of methods and use perspectives in prevention of arteriosclerosis), G Ital Chim Clin. 1982;7:127–138
  41. World Health Organization . International classification of diseases and causes of death. 9th Revision. Geneva: WHO; 1975;
  42. Reaven GM. The metabolic syndrome: requiescat in pace. Clin Chem. 2005;51:931–938
  43. Grundy SM. The metabolic syndrome is still alive. Clin Chem. 2005;51:1352–1357
  44. Menotti A, Lanti M. The metabolic syndrome, the Guy syndrome and the hypofit syndrome. J Cardiovasc Med. 2007;8:397–398

PII: S0939-4753(09)00276-2

doi: 10.1016/j.numecd.2009.11.001

Nutrition, Metabolism & Cardiovascular Diseases
Volume 21, Issue 5 , Pages 315-322 , May 2011

Article Tools

* Image Usage & Resolution